Mirabegron

• Overactive Bladder
• Urge Urinary Incontinence
• Neurogenic Detrusor Overactivity

Mirabegron, marketed in the United States as Myrbetriq, is a selective beta-3 adrenergic receptor agonist used to treat overactive bladder (OAB) and, in pediatric patients aged three years and older, neurogenic detrusor overactivity. It was the first agent in its class and represented an important conceptual departure from the antimuscarinic medications that had dominated OAB therapy for decades. Where antimuscarinics relax the detrusor by blocking acetylcholine signaling — at the cost of dry mouth, constipation, blurred vision, and cognitive effects — mirabegron achieves bladder relaxation through a different receptor system entirely, sparing patients much of the anticholinergic burden that has been linked in observational studies to increased dementia risk in older adults.

Mechanism of Action

The human bladder contains all three beta-adrenergic receptor subtypes (beta-1, beta-2, and beta-3), but beta-3 receptors are by far the most numerous on detrusor smooth muscle. During the storage phase of the micturition cycle, sympathetic activity releases norepinephrine, which acts on these beta-3 receptors to relax the detrusor and allow the bladder to fill at low pressure. Mirabegron is a selective beta-3 agonist that mimics this physiologic effect, increasing intracellular cyclic AMP through G-protein coupled signaling, activating protein kinase A, and producing detrusor relaxation. The result is greater functional bladder capacity, fewer involuntary detrusor contractions during filling, and reduced urgency and frequency. Because mirabegron does not block muscarinic receptors, salivary, gastrointestinal, ocular, and central nervous system cholinergic functions are largely preserved. The drug's selectivity for beta-3 over beta-1 and beta-2 is high but not absolute, which explains the observed but modest effects on heart rate and blood pressure. For patients exploring related care, our genitourinary specialty page offers a broader overview.

Clinical Use

Mirabegron is FDA-approved for adults with OAB symptoms — urgency, frequency, and urge urinary incontinence — and for pediatric patients aged three years and older with neurogenic detrusor overactivity, often associated with spina bifida. Within the OAB algorithm, behavioral therapy (bladder training, fluid management, pelvic floor exercises) remains first-line per the American Urological Association guidelines. Pharmacotherapy is added when behavioral measures fall short. Mirabegron is increasingly favored over antimuscarinics as first-line drug therapy in older adults because of the reduced anticholinergic burden, which matters significantly in patients on multiple central-acting medications or with baseline cognitive concerns. In patients with partial response to either an antimuscarinic or mirabegron alone, combination therapy with solifenacin (the SYNERGY trials) has been shown to improve both incontinence episodes and micturition frequency without prohibitive side effects. Patients who fail or cannot tolerate first- and second-line therapies may be candidates for sacral neuromodulation, intradetrusor onabotulinumtoxinA, or percutaneous tibial nerve stimulation. For background reading, the Urology Care Foundation maintains an excellent OAB resource.

How to Take It

Mirabegron extended-release tablets come in 25 mg and 50 mg strengths. The starting dose for adults is 25 mg once daily, which can be increased to 50 mg once daily after eight weeks based on response and tolerability. Tablets must be swallowed whole with water and should not be crushed, chewed, or split, because the extended-release matrix controls the absorption profile. The medication can be taken with or without food, though consistent timing — same time each day — gives the most stable plasma concentrations. For pediatric neurogenic detrusor overactivity, weight-banded dosing using the granule formulation or tablets is used. If a dose is missed and remembered within 12 hours, take it; if more than 12 hours have passed, skip and resume the normal schedule the next day. Symptom relief is often noticeable within 2 to 4 weeks, with maximal response by 8 to 12 weeks; patients should be counseled not to expect immediate effects. Common early experiences include mild dry mouth (less than antimuscarinics), occasional headache, and modest blood pressure rise.

Monitoring and Follow-Up

Blood pressure should be measured at baseline and within four to eight weeks of starting therapy, then periodically — particularly important because mirabegron can raise systolic and diastolic blood pressure by a few mmHg on average, with larger increases in some individuals. Patients with stage 2 hypertension (160/100 mmHg or higher) or uncontrolled hypertension should generally not be started on the drug; in patients with controlled hypertension, blood pressure should be tracked and the medication held if pressures rise unacceptably. A baseline assessment of bladder symptoms — voiding diary, urgency episodes, incontinence episodes, and quality of life — provides the comparator for response. Post-void residual measurement should be considered in patients with bladder outlet obstruction symptoms, particularly men with benign prostatic hyperplasia, because mirabegron can theoretically contribute to urinary retention. Heart rate should be checked, particularly in patients with arrhythmia history. Patients on warfarin or digoxin should have INR or digoxin levels monitored. Reviewing your understanding blood pressure numbers and controlling high blood pressure guides builds a useful longitudinal record alongside home readings.

Special Populations

In elderly patients, no formal dose adjustment is required, but the lower 25 mg starting dose with cautious titration is prudent — and the avoidance of anticholinergic burden is a particular advantage in this group. Renal impairment requires attention: in severe disease (eGFR 15 to 29 mL/min/1.73 m2), the maximum is 25 mg daily; mirabegron is not recommended in end-stage renal disease or eGFR below 15. In moderate hepatic impairment (Child-Pugh B), the maximum is also 25 mg daily; severe hepatic impairment (Child-Pugh C) is a contraindication. Pregnancy data are limited and the drug should be used only if benefit clearly outweighs risk; lactation data are absent. Pediatric use is approved for neurogenic detrusor overactivity in children aged three and older, with weight-based dosing. Patients with bladder outlet obstruction or those taking antimuscarinics for OAB simultaneously face increased urinary retention risk and should be monitored. Mirabegron itself inhibits CYP2D6, raising exposure of substrates such as metoprolol and desipramine; clinicians should consider lower doses of those agents.

When to Contact Your Doctor

Seek immediate care for facial, lip, or tongue swelling, throat tightness, or trouble breathing — angioedema has been reported with mirabegron and is a medical emergency. Inability to urinate, severe lower abdominal pain, or markedly slowed urine stream may indicate retention and warrants prompt evaluation. New chest pain, palpitations, or markedly elevated home blood pressure readings (systolic above 180 or diastolic above 110) deserve urgent attention. Persistent headache, dizziness on standing, or unexplained heart rate changes should be reported. New urinary tract infections, fever, or flank pain may signal an unrelated condition that the medication's symptom relief could mask. The MedlinePlus mirabegron page and the FDA Myrbetriq label provide additional resources for patients and families.

Practical Tips for Daily Use

Mirabegron works best as part of a comprehensive bladder-management plan rather than a standalone fix. Track your fluid intake — many patients with OAB unintentionally drink either too much (increasing urgency) or too little (concentrating urine and worsening irritation); a target of about 1.5 to 2 liters per day, spread across the day rather than concentrated in the evening, is reasonable for most. Caffeine and alcohol are both bladder irritants; reducing intake or shifting it earlier in the day often improves symptoms substantially. Carbonated beverages, artificial sweeteners, and acidic juices similarly aggravate symptoms in many patients — a brief elimination trial can be revealing. Bladder training (gradually extending the interval between voids) and pelvic floor exercises remain valuable adjuncts. Take the medication at the same time each day to maintain steady levels. If you take other medications, ask your pharmacist to flag any CYP2D6 substrates — particularly metoprolol and certain antidepressants — that may need dose adjustment. Monitor your blood pressure at home weekly during the first two months; many drugstore and home cuffs are accurate enough for tracking trends, and unexpected rises should prompt a call to your prescriber rather than a wait until your next visit.

Working With Your Care Team

Overactive bladder is treatable, and the right combination of behavioral strategies and medication can substantially improve daily quality of life. Schedule a visit with our internal medicine team to evaluate symptoms, review options, and tailor a plan that respects your other medications and goals.